Formycon

Formycon (FYB) investor relations material

Formycon Q3 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.

Q3 2025 earnings summary13 Nov, 2025

Executive summary

Revenue and earnings for the first nine months of 2025 aligned with expectations, with full-year guidance confirmed and significant pipeline progress achieved, including launches, regulatory milestones, and expanded partnerships.
Operational expansion advanced through development, financing, and competitiveness, with a strategic focus on biosimilars, geographic diversification, and leveraging regulatory changes for cost efficiency.
Commercial ramp-up for FYB202 (Stelara® biosimilar) underway, with strong Q4 sales momentum anticipated in the US and Europe.
Achieved key milestones: completion of FYB206 phase I recruitment, first registration for FYB201 in sub-Saharan Africa, and settlement for FYB203 enabling US launch in Q4 2026.
Liquidity strengthened by a €70 million bond issue and increased cash position.

Financial highlights

Group revenue for 9M 2025 was €19.5 million, down from €41.1 million in 9M 2024, reflecting a shift from one-time license payments to recurring commercialization revenues.
EBITDA for 9M 2025 was €-21.4 million (9M 2024: €-17.7 million); adjusted EBITDA was €-21.7 million (9M 2024: €2.9 million).
Working capital increased to €83.2 million at Q3 end, supported by bond issuance.
Cash and cash equivalents at period end were €79.5 million, up from €41.8 million at the end of 2024.
Net loss for 9M 2025 was €-60.4 million, compared to €-20.9 million in 9M 2024.

Outlook and guidance

Full-year 2025 revenue guidance of €55–65 million confirmed, with major revenue streams expected in Q4 from FYB202 and FYB206.
EBITDA and adjusted EBITDA guidance unchanged at €-20 million to €-10 million; positive EBITDA targeted by 2026, or at the latest by 2027.
Q4 revenue drivers include increased FYB202 royalties and anticipated licensing deals for FYB206.

FYB201 US re-launch strategy details.

How do new US regs streamline development?

How will recurring sales drive 2026 EBITDA?

FYB206: How Phase III waiver accelerates deals?

FYB202 U.S. market penetration: What's the outlook?

How will reduced biosimilar development costs impact P&L?

Partial view of Summaries dataset, powered by Quartr API

AI can get things wrong. Verify important information.

Research faster. Power your platform.

Latest events from Formycon

View more events

Next Formycon earnings date

Q4 202526 Mar, 2026

Companies

Formycon

Your earnings  season toolkit.

Download

Free on both iOS & Android.

Next Formycon earnings date

Q4 202526 Mar, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.

Leroy DaleyApp Store

One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.

Eferix Drawings Google Play

This is genuinely one of the cleanest and fastest finance apps out there to track the market.

anuj283App Store

Leroy DaleyApp Store

One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.

Eferix Drawings Google Play

This is genuinely one of the cleanest and fastest finance apps out there to track the market.

anuj283App Store

I can't remember the last time an app had such a positive impact on my investment process.

@ankurshah47_ x.com

Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.

Amina0781App Store

Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.

@theshortbearx.com

I can't remember the last time an app had such a positive impact on my investment process.

@ankurshah47_ x.com

Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.

Amina0781App Store

Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.

@theshortbearx.com

I’m actually shocked at just how much I like Quartr. If you’re an analyst & need a strong web tool + mobile app that syncs properly, saves you from manually dialing into calls.

@endthepods x.com

A must have for every investor. includes all quarterly reports with earnings calls and transcripts in single app

Abdulla AlnaamaGoogle Play